Evidence map›Paper›PMID 37385275›Full record

Trial reportLancet (London, England)2023

Tirzepatide once weekly for the treatment of obesity in people with type 2 diabetes (SURMOUNT-2): a double-blind, randomised, multicentre, placebo-controlled, phase 3 trial.

W Timothy Garvey, Juan P Frias, Ania M Jastreboff, Carel W le Roux, Naveed Sattar, Diego Aizenberg, Huzhang Mao, Shuyu Zhang, Nadia N Ahmad, Mathijs C Bunck and 3 more

3 registry-linked trialsOpen access · greenAbstract readRandomized Controlled TrialMulticenter StudyClinical Trial, Phase III
PubMed Publisher
In one paragraph

Trial report in Lancet (London, England), 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to 3 registered trials, which are not on this map. Cited by 401 papers, 17 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
401citing papers in PubMed, 17 pooled it
124.5field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT07731256 phase2not yet recruitingstarted 2027, after this paper: background citation

A Randomized-Controlled Trial of Semaglutide for Patients With Chronic Low Back Pain and Obesity

Ran2027Enrolled250Registered outcomes13Posted comparisons0ConditionsChronic Lower Back Pain, glp1 Agonist, Lower Back Pain, Obesity (BMI>30)ArmsPlacebo (administered by PDS290 pen-injector), Semaglutide (administered by PDS290 pen-injector)
PMID 39476339PMID 37351564PMID 20007994PMID 27537761PMID 28192789PMID 29573870PMID 31797139PMID 32125402PMID 32520773PMID 34051018PMID 35507483PMID 35606809other papers from this trial
Open the trial in the graph
NCT07226947 narecruitingnot on this mapstarted 2025, after this paper: background citation

BIA Monitoring and Exercise for the Prevention of Muscle Loss With Incretin Therapy (BICEP Study)

TypeinterventionalSponsorMassachusetts General HospitalRan2025 to 2027Enrolled100ConditionsObesity, Body CompositionArmsSmartwatch activity and body composition monitor, General guidance on recommended exercise
NCT07756359 phase4not yet recruitingnot on this mapstarted 2026, after this paper: background citation

Efficacy of the Dual GIP - GLP-1 Receptor Agonist Tirzepatide in Patients With an Ileal Pouch-anal Anastomosis (IPAA) and Chronic High Bowel Frequency (I8F-NS-X008)

TypeinterventionalSponsorUniversity of North Carolina, Chapel HillRan2026 to 2027Enrolled20ConditionsPouch, Ileal, Pouches, Ileoanal, Bowel Diseases, InflammatoryArmsTirzepatide, Loperamide, Diphenoxylate/Atropine
3 · Its place in the literature

Who cites it

401 citing papers in PubMed, 17 syntheses or guidelines pooled it, 619 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Pooled it
  4. Pooled it
  5. Pooled it
  6. Pooled it
  7. Pooled it
  8. Guideline
  9. Pooled it
  10. Pooled it
  11. Effect of Tirzepatide on arrhythmic, major cardiovascular, and neurological outcomes in patients with type 2 diabetes: A systematic review and meta-analysis.Neurological sciences : official journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology · 2025 · on this map
    Pooled it
  12. Pooled it
  13. Pooled it
  14. Pooled it
  15. Efficacy and Safety of Tirzepatide on Weight Loss in Patients Without Diabetes Mellitus: A Systematic Review and Meta-Analysis of Randomized Controlled Trials.Obesity reviews : an official journal of the International Association for the Study of Obesity · 2025 · on this map
    Pooled it
  16. CMAJ : Canadian Medical Association journal = journal de l'Association medicale canadienne · 2025
    Guideline
  17. Pharmacotherapy for obesity management in adults: 2025 clinical practice guideline update.CMAJ : Canadian Medical Association journal = journal de l'Association medicale canadienne · 2025
    Guideline
  18. Trial
  19. Trial
  20. Trial

341 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

13 authors at 7 institutions in 3 countries.

W Timothy GarveyUAB Diabetes Research Center, University of Alabama at Birmingham, Birmingham, AL, USA. Electronic address: garveyt@uab.edu.
Juan P FriasVelocity Clinical Research, Los Angeles, CA, USA.
Ania M JastreboffDepartment of Medicine (Endocrinology and Metabolism) and Pediatrics (Pediatric Endocrinology), Yale University School of Medicine, New Haven, CT, USA.
Carel W le RouxDiabetes Complications Research Centre, University College Dublin, Dublin, Ireland; Diabetes Research Centre, Ulster University, Coleraine, UK.
Naveed SattarSchool of Cardiovascular and Metabolic Health, University of Glasgow, Glasgow, UK.
Diego AizenbergCentro Médico Viamonte, Buenos Aires, Argentina.
Huzhang MaoEli Lilly and Company, Indianapolis, IN, USA.
Shuyu ZhangEli Lilly and Company, Indianapolis, IN, USA.
Nadia N AhmadEli Lilly and Company, Indianapolis, IN, USA.
Mathijs C BunckEli Lilly and Company, Indianapolis, IN, USA.
Imane BenabbadEli Lilly and Company, Indianapolis, IN, USA.
Xiaotian M ZhangEli Lilly and Company, Indianapolis, IN, USA.
SURMOUNT-2 investigators
Eli Lilly (United States) · USVelocity Clinical Research (United States) · USUniversity of Alabama at Birmingham · USUniversity College Dublin · IEUniversity of Glasgow · GBUniversity of Ulster · GBYale University · US

Funding

North Carolina Translational and Clinical Sciences Institute (NC TraCS)UM1TR004406 · UNIV OF NORTH CAROLINA CHAPEL HILL · 2025 to 2025
$8.6M
NCATS NIH HHS UM1 TR004406
6 · The paper itself

Abstract

backgroundWeight reduction is essential for improving health outcomes in people with obesity and type 2 diabetes. We assessed the efficacy and safety of tirzepatide, a glucose-dependent insulinotropic polypeptide and glucagon-like peptide-1 receptor agonist, versus placebo, for weight management in people living with obesity and type 2 diabetes.

methodsThis phase 3, double-blind, randomised, placebo-controlled trial was conducted in seven countries. Adults (aged ≥18 years) with a body-mass index (BMI) of 27 kg/m

findingsBetween March 29, 2021, and April 10, 2023, of 1514 adults assessed for eligibility, 938 (mean age 54·2 years [SD 10·6], 476 [51%] were female, 710 [76%] were White, and 561 [60%] were Hispanic or Latino) were randomly assigned and received at least one dose of tirzepatide 10 mg (n=312), tirzepatide 15 mg (n=311), or placebo (n=315). Baseline mean bodyweight was 100·7 kg (SD 21·1), BMI 36·1 kg/m

interpretationIn this 72-week trial in adults living with obesity and type 2 diabetes, once-weekly tirzepatide 10 mg and 15 mg provided substantial and clinically meaningful reduction in bodyweight, with a safety profile that was similar to other incretin-based therapies for weight management.

fundingEli Lilly and Company.

Indexed as

Diabetes Mellitus, Type 2AdolescentAdultBody WeightDouble-Blind MethodFemaleGlucagon-Like PeptidesHumansHypoglycemic AgentsMaleMiddle AgedObesityTirzepatideTreatment OutcomeGlucagon-Like PeptidesHypoglycemic AgentsTirzepatide

Identifiers

PMID37385275
OpenAlexW4382050932

What Socratic holds

Texttitle and abstract
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.